News Stories

Julie E. Lang, MD, with patient Alise Bennett.

The Arizona Cancer Center is participating in a groundbreaking nationwide breast cancer study.

The Phase I team

The Arizona Cancer Center’s Phase I Clinical Trials Program is the only place in Southern Arizona where patients can get access to cutting-edge investigational treatments.

Sourav Ghosh

Funded by the National Institutes of Health, the project focuses on the discovery of a deranged signaling protein that disrupts the proper migration of cells in the developing brain. The scientists will test whether it could be a target for new cancer-fighting drugs.

Joanne M. Jeter, MD

Arizona Cancer Center member Joanne M. Jeter, MD, has received a 2010 National Institutes of Health Merit Award for her membership on the PDQ Cancer Genetics Editorial Board.

The Arizona Cancer Center’s Cancer Prevention and Control Fellowship Program has received a five-year, $2.5 million grant renewal. The training program has had National Cancer Institute funding since 1998.

Worldwide Neuroendocrine Cancer Awareness Day, held Nov. 10, brought awareness about neuroendocrine tumors (NET). The Arizona Cancer Center is among the institutions involved in the treatment study of NET, comparing standard treatment with a novel therapy.

Arthur Gmitro, PhD, and Andrew Rouse, PhD, have been awarded $1.2 million by the National Institutes of Health to develop and clinically validate a real-time multi-spectral confocal microendoscope for in vivo diagnosis of ovarian cancer.

M. Elena Martínez, PhD, MPH

M. Elena Martínez, PhD, MPH, co-director of the Arizona Cancer Center’s Cancer Prevention and Control Program and professor of epidemiology at the Mel and Enid Zuckerman College of Public Health, is The University of Texas M.D. Anderson Cancer Center distinguished alumnus for 2010.

Alison T. Stopeck, MD

Arizona Cancer Center physician/scientist Alison T. Stopeck, MD, is the lead author of a paper appearing in the Nov. 8 issue of the Journal of Clinical Oncology reporting on the pain reducing  and complication prevention benefits of a new drug in breast cancer patients whose disease has spread to the bone.

The Better Than Ever training and fundraising program distributed $120,000 to fund five research grants focusing on women's cancers at the Arizona Cancer Center.